ASCO 2018: Everolimus Is Linked to a Significant Increase in Metabolic, Pulmonary, Dermatologic, and Hematologic Toxicities in Advanced Renal Cell Carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.